Skip to main content

Table 7 Responsiveness to treatment: change in WPAI scores following effective treatment interventions in prospective, open-label studies

From: Psychometric validation of the work productivity and activity impairment questionnaire in ulcerative colitis: results from a systematic literature review

  Change (mean WPAI scores at Week 8 - mean WPAI scores at baseline)
Study N Treatment regimen Treatment duration Absenteeism Presenteeism OWI Activity Impairment
Travis 2017 [29] 446 ADA (initial 160/80 mg, 40 mg EOW at Week 4) 26 weeks −11.4 −24.5 − 29.2 −27.2
Willshire 2014 [40] 404 MMX mesalamine 4.8 g/day 8 weeks − 7.6 −20.6 −23.4 −24.1
Yarlas 2015a [36] 103 MMX mesalamine 2.4–4.8 g/day 8 weeks − 4.0 −12.3 − 13.8 −14.2
Weighted mean changea − 9.0 −21.5 −25.1 −24.5
Median change −7.6 − 20.6 −23.4 −24.1
  1. ADA adalimumab, EOW every other week, MMX multimatrix, OWI Overall Work Impairment, WPAI Work Productivity and Activity Impairment questionnaire
  2. Values printed in BOLD indicating those exceeding established thresholds indicating clinically important change
  3. aWeighted by sample size